secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027545
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4
--------------------------------------------------------------------------------

- Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.
- Revenue fell to $3.2M from $4.6M YoY, driven by lower Roche collaboration revenue.
- Cash $45.9M; expected to fund operations into Q4 2024.
- OpRegen Phase 2a enrolling; FDA meeting response enables OPC1 delivery device IND amendment in Q4.
- VAC2 Phase 1 topline: five of eight stable disease; three of eight reached 2-year survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/0001493152-23-027545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer